Chondroitin sulfate as a marker of bone resorption
US5869273A · kind A · utility
4Cited by
7References
36Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 13, 1996 |
| Grant date | Feb 9, 1999 |
| Priority date | — |
| Expiry date | Sep 13, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/25125
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The subject invention provides methods and kits for detecting increased bone resorption in patients. These methods and kits use chondroitin sulfate, a glycosaminoglycan, as a marker for bone resorption. Levels of chondroitin sulfate are detected in samples of urine or serum taken from patients. Measurements of chondroitin sulfate levels are made by methods such as fluorophore-assisted carbohydrate electrophoresis (FACE). Knowledge of increased bone resorption rates is useful in diagnosis of bone disorders such as osteoporosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.